427 related articles for article (PubMed ID: 34678857)
1. Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
Shamseya AM; Hussein WM; Elnely DA; Adel F; Header DA
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e803-e809. PubMed ID: 34678857
[TBL] [Abstract][Full Text] [Related]
2. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
Husain N; Tokoro K; Popov JM; Naides SJ; Kwasny MJ; Buchman AL
J Clin Gastroenterol; 2013 Mar; 47(3):246-51. PubMed ID: 23269308
[TBL] [Abstract][Full Text] [Related]
3. Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease.
Manon-Jensen T; Sun S; Lindholm M; Domislović V; Giuffrida P; Brinar M; Mazza G; Pinzani M; Krznarić Z; Di Sabatino A; Karsdal MA; Mortensen JH
United European Gastroenterol J; 2021 Mar; 9(2):268-278. PubMed ID: 33351719
[TBL] [Abstract][Full Text] [Related]
4. Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn's Disease.
Piechota-Polanczyk A; Włodarczyk M; Sobolewska-Włodarczyk A; Jonakowski M; Pilarczyk A; Stec-Michalska K; Wiśniewska-Jarosińska M; Fichna J
Dig Dis Sci; 2017 Jun; 62(6):1511-1517. PubMed ID: 28391416
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?
Ansari N; Abdulla J; Zayyani N; Brahmi U; Taha S; Satir AA
J Clin Pathol; 2006 Oct; 59(10):1066-72. PubMed ID: 16565224
[TBL] [Abstract][Full Text] [Related]
7. Urotensin II levels in patients with inflammatory bowel disease.
Alicic D; Martinovic D; Rusic D; Zivkovic PM; Tadin Hadjina I; Vilovic M; Kumric M; Tokic D; Supe-Domic D; Lupi-Ferandin S; Bozic J
World J Gastroenterol; 2021 Sep; 27(36):6142-6153. PubMed ID: 34629825
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
[TBL] [Abstract][Full Text] [Related]
9. Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort.
Greuter T; Porchet F; Braga-Neto MB; Rossel JB; Biedermann L; Schreiner P; Scharl M; Schoepfer AM; Safroneeva E; Straumann A; Rogler G; Vavricka SR
United European Gastroenterol J; 2020 Dec; 8(10):1196-1207. PubMed ID: 33276710
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.
Khanna R; Ma C; Jairath V; Vande Casteele N; Zou G; Feagan BG
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):727-736.e2. PubMed ID: 33338657
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging to distinguish the type and severity of pediatric inflammatory bowel diseases.
Durno CA; Sherman P; Williams T; Shuckett B; Dupuis A; Griffiths AM
J Pediatr Gastroenterol Nutr; 2000 Feb; 30(2):170-4. PubMed ID: 10697136
[TBL] [Abstract][Full Text] [Related]
12. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS.
Takač B; Mihaljević S; Glavaš-Obrovac L; Kibel A; Suver-Stević M; Canecki-Varžić S; Samardžija M; Rajkovac I; Kovač D; Štefanić M
Acta Clin Croat; 2020 Mar; 59(1):67-80. PubMed ID: 32724277
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.
Busingye D; Pollack A; Chidwick K
PLoS One; 2021; 16(5):e0252458. PubMed ID: 34043730
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD).
Siloşi I; Boldeanu MV; Mogoantă SŞ; Ghiluşi M; Cojocaru M; Biciuşcă V; Cojocaru IM; Avrămescu CS; Gheonea DI; Siloşi CA; Turculeanu A
Rom J Morphol Embryol; 2014; 55(4):1317-24. PubMed ID: 25611261
[TBL] [Abstract][Full Text] [Related]
15. Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.
Romeo S; Neri B; Mossa M; Calabrese E; Lolli E; Sena G; Gesuale C; Chiaramonte C; Biancone L
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):844-851. PubMed ID: 33136723
[TBL] [Abstract][Full Text] [Related]
16. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
[TBL] [Abstract][Full Text] [Related]
17. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.
Miranda-García P; Chaparro M; Gisbert JP
Gastroenterol Hepatol; 2016 Oct; 39(8):508-15. PubMed ID: 27020243
[TBL] [Abstract][Full Text] [Related]
18. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
[TBL] [Abstract][Full Text] [Related]
19. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
Tang R; Yang G; Zhang S; Wu C; Chen M
Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
[TBL] [Abstract][Full Text] [Related]
20. Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.
Williams AD; Korolkova OY; Sakwe AM; Geiger TM; James SD; Muldoon RL; Herline AJ; Goodwin JS; Izban MG; Washington MK; Smoot DT; Ballard BR; Gazouli M; M'Koma AE
PLoS One; 2017; 12(8):e0179710. PubMed ID: 28817680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
